"The industry's output of new drugs has risen only modestly in the last two decades despite a more than sixfold increase [...] in R&D spending, to more than $30 billion annually. In the last few years, the output has actually declined."
 "The perceived paucity of new drugs in company pipelines has become a preoccupation of the industry and of Wall Street."
 "No one has yet found a reliable way to fill the pipeline."
 "Over the last 25 years, a parade of technologies has promised to transform drug development: genetic engineering, rational drug design, combinatorial chemistry, improved screening -- and now, genomics. Yet the time spent to develop a drug, not counting the months consumed by government review, has lengthened to more than 11 years from about 9 years in the 1980's [...], and the cost has more than doubled."
 "The industry's failure rate, a big part of its costs, has not declined. The odds are just dreadful, and they seem to be getting worse'' [said] Julie A. Olson, a VP for licensing at Pfizer."

 "Drug discovery: the pharmaceutical industry needs a shot in the arm. Where will that innovation come from?"

«	page 3/3	»
	1